HMN:NYSEHorace Mann Educators Corporation Analysis
Data as of 2026-05-21 - not real-time
$47.65
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Horace Mann (HMN) is trading at $47.65, comfortably above its 20‑day ($45.53), 50‑day ($44.34) and 200‑day ($44.67) simple moving averages, indicating a bullish price trend. The RSI sits at 69.5, approaching overbought territory but still below the 70 threshold, while the MACD line (0.48) remains above its signal (0.31), reinforcing short‑term upside momentum. The stock’s PE ratio of 11.97 is well below the industry average of 16.69, and the DCF‑derived fair value suggests roughly a 9% upside, signaling undervaluation. With a dividend yield of 3.08% and a modest payout ratio of 35%, the dividend appears sustainable and attractive for income‑focused investors.
Fundamentally, HMN posted $1.71 B in revenue with 3.1% growth and a solid 38.8% gross margin, while operating and net margins of 13.9% and 9.6% reflect healthy profitability. EPS is accelerating, with forward EPS projected at $5.06 versus trailing $3.98, and free cash flow of $275 M supports ongoing operations and dividend payments. The balance sheet shows moderate leverage (debt‑to‑equity ~40%) and low beta (0.22), indicating limited market volatility; 30‑day price volatility is 17.5%, and volume remains stable. Recent earnings calls highlighted a 20% YoY rise in core EPS and a 6% increase in insurance and fee revenue, offset by a slight revenue miss versus estimates, underscoring resilient earnings growth amid modest top‑line pressure.
Fundamentally, HMN posted $1.71 B in revenue with 3.1% growth and a solid 38.8% gross margin, while operating and net margins of 13.9% and 9.6% reflect healthy profitability. EPS is accelerating, with forward EPS projected at $5.06 versus trailing $3.98, and free cash flow of $275 M supports ongoing operations and dividend payments. The balance sheet shows moderate leverage (debt‑to‑equity ~40%) and low beta (0.22), indicating limited market volatility; 30‑day price volatility is 17.5%, and volume remains stable. Recent earnings calls highlighted a 20% YoY rise in core EPS and a 6% increase in insurance and fee revenue, offset by a slight revenue miss versus estimates, underscoring resilient earnings growth amid modest top‑line pressure.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Technical bullishness with price above key SMAs
- Strong dividend yield and sustainable payout
- Momentum from recent EPS beat
Medium Term
1–3 yearsNeutral
Model confidence: 8/10
Key Factors
- Undervalued valuation metrics relative to peers
- Steady earnings growth and free cash flow generation
- Low beta and moderate volatility supporting stable returns
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Attractive dividend yield with long‑term sustainability
- Consistent profitability and modest revenue growth
- Favorable risk profile due to low leverage and US‑centric operations
Key Metrics & Analysis
Financial Health
Revenue Growth3.10%
Profit Margin9.63%
P/E Ratio12.0
ROE11.74%
ROA1.03%
Debt/Equity40.40
P/B Ratio1.3
Op. Cash Flow$473.7M
Free Cash Flow$275.6M
Industry P/E16.7
Technical Analysis
TrendNeutral
RSI69.5
Support$43.65
Resistance$47.72
MA 20$45.53
MA 50$44.34
MA 200$44.67
MACDBullish
VolumeStable
Fear & Greed Index91.5
Valuation
Fair Value$89.21
Target Price$52.00
Upside/Downside9.13%
GradeUndervalued
TypeBlend
Dividend Yield3.08%
Risk Assessment
Beta0.22
Volatility17.55%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.